Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer
R
Roberto Pili, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Administratively Closed
100 years or below
All
Phase
N/A
2 Locations
Brief description of study
The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.
Detailed description of study
The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: prostate cancer
-
Age: 100 years or below
-
Gender: All
Updated on
25 Mar 2025.
Study ID: 1706003129 (IUSCC-0634)
